Juliana Guarente
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juliana Guarente has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Angelica Vivero
Department of Pathology and Genomic Medicine Thomas Jefferson University Hospital Philadelphia Pennsylvania USA
3 shared publications - Julie Katz Karp
Department of Pathology and Genomic Medicine Thomas Jefferson University Hospital Philadelphia Pennsylvania USA
3 shared publications - Jeremy W. Jacobs
Department of Pathology, Microbiology, and Immunology Vanderbilt University Nashville Tennessee USA
2 shared publications Jovanna Everetts
Department of Pathology and Genomic Medicine Thomas Jefferson University Hospital Philadelphia Pennsylvania USA
2 shared publications- Mary Harach
Department of Pathology and Genomic Medicine Thomas Jefferson University Hospital Philadelphia Pennsylvania USA
2 shared publications Tiffany Bohr
Nemours Children's Hospital Wilmington Delaware USA
2 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2397-2409
Current advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- 31 August 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2397-2409
Open AccessCurrent advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies ( AABB ) Clinical Transfusion Medicine Committee
- 26 July 2026
- Published by Wiley in Transfusion
- Vol. 66 (9) , 1864
In reply
- Open Access
- 18 June 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (3) , e70146
Variation in Chronic Automated Red Cell Exchange Practices for Sickle Cell Disease: Insights Into Isovolemic Hemodilution Use
Prior surveys of chronic automated red blood cell exchange (RCE) for patients with sickle cell disease (SCD) have identified considerable procedural variability, especially with the use of isovolemic hemodilution red blood cell exchange (IHD‐RCE). We conducted a survey of chronic RCE practices among American Society for Apheresis (ASFA) members to identify opportunities for practice harmonization and future studies. The ASFA SCD Research Subcommittee developed a 72‐item survey of chronic RCE practices, with a focus on IHD‐RCE. The survey was validated internally and distributed by email to all ASFA members from September 2024 to February 2025. One survey response from each institution was retained for data analysis. Descriptive statistics were performed. Sixty‐two survey responses, including three from international institutions, were retained for analysis. Sixty‐one percent of respondents (38/62) reported using at least one fixed RCE target, with end hematocrit being the most common fixed parameter (40%, 25/62), followed by fraction of cells remaining (31%, 19/62) and hemoglobin S% (27%, 17/62). Most respondents (60%, 37/61) performed IHD‐RCE at their institution, though other details such as the minimum hematocrit, exclusion criteria, and response to adverse effects were variable. Consistent pre‐ and post‐RCE laboratory monitoring practices were reported. Consistent with earlier surveys, procedural variability in chronic RCE practices for patients with SCD is observed. This highlights opportunities to compare outcomes where practice variability exists. Consensus guidelines based on institutional practices with optimal outcomes should be developed.
- 18 June 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (3) , e70146
Open AccessVariation in Chronic Automated Red Cell Exchange Practices for Sickle Cell Disease: Insights Into Isovolemic Hemodilution Use
Prior surveys of chronic automated red blood cell exchange (RCE) for patients with sickle cell disease (SCD) have identified considerable procedural variability, especially with the use of isovolemic hemodilution red blood cell exchange (IHD‐RCE). We conducted a survey of chronic RCE practices among American Society for Apheresis (ASFA) members to identify opportunities for practice harmonization and future studies. The ASFA SCD Research Subcommittee developed a 72‐item survey of chronic RCE practices, with a focus on IHD‐RCE. The survey was validated internally and distributed by email to all ASFA members from September 2024 to February 2025. One survey response from each institution was retained for data analysis. Descriptive statistics were performed. Sixty‐two survey responses, including three from international institutions, were retained for analysis. Sixty‐one percent of respondents (38/62) reported using at least one fixed RCE target, with end hematocrit being the most common fixed parameter (40%, 25/62), followed by fraction of cells remaining (31%, 19/62) and hemoglobin S% (27%, 17/62). Most respondents (60%, 37/61) performed IHD‐RCE at their institution, though other details such as the minimum hematocrit, exclusion criteria, and response to adverse effects were variable. Consistent pre‐ and post‐RCE laboratory monitoring practices were reported. Consistent with earlier surveys, procedural variability in chronic RCE practices for patients with SCD is observed. This highlights opportunities to compare outcomes where practice variability exists. Consensus guidelines based on institutional practices with optimal outcomes should be developed.
- Open Access
- 12 April 2026
- Published by Wiley in Transfusion
- Vol. 66 (6) , 1108-1112
Routine transfusion of Rh(D)‐positive RBCs to Rh(D)‐negative patients designated as do not resuscitate conserves Rh(D)‐negative red blood cell inventory
Background: A minority of blood donors are Rh(D)‐negative, and Rh(D)‐negative red blood cell (RBC) products are often overutilized. As such, Rh(D)‐negative RBCs may be difficult to maintain in blood bank inventory. Study Design and Methods: We changed our blood bank laboratory policy to approve non‐alloimmunized Rh(D)‐negative patients to receive Rh(D)‐positive RBCs for routine transfusion under defined criteria. Those criteria included Rh(D)‐negative males (all ages) and females (aged >50 years) who were designated as do not resuscitate (DNR), either with or without intubation, in the electronic medical record. Results: From August 15, 2024 through August 15, 2025, a total of 204 Rh(D)‐negative patients met the above criteria and were approved to receive routine Rh(D)‐positive RBC transfusions. Within that group, 23 patients received Rh(D)‐positive RBCs. The remaining patients either did not require transfusion or were issued Rh(D)‐negative RBC units. Since implementing this practice, a total of 68 Rh(D)‐negative units were conserved during this time frame. Notably, 28 of the 68 units (41%) were type O, Rh(D)‐negative. Discussion: Rh(D)‐positive RBCs can be routinely given to non‐alloimmunized Rh(D)‐negative patients who are not at risk for developing hemolytic disease of the fetus and newborn (HDFN). By creating clear guidelines for the routine administration of Rh(D)‐positive RBCs to patients who are not at risk for HDFN, the inventory of Rh(D)‐negative RBC units can be directed to those patients who would most benefit from this limited resource.
- 12 April 2026
- Published by Wiley in Transfusion
- Vol. 66 (6) , 1108-1112
Open AccessRoutine transfusion of Rh(D)‐positive RBCs to Rh(D)‐negative patients designated as do not resuscitate conserves Rh(D)‐negative red blood cell inventory
Background: A minority of blood donors are Rh(D)‐negative, and Rh(D)‐negative red blood cell (RBC) products are often overutilized. As such, Rh(D)‐negative RBCs may be difficult to maintain in blood bank inventory. Study Design and Methods: We changed our blood bank laboratory policy to approve non‐alloimmunized Rh(D)‐negative patients to receive Rh(D)‐positive RBCs for routine transfusion under defined criteria. Those criteria included Rh(D)‐negative males (all ages) and females (aged >50 years) who were designated as do not resuscitate (DNR), either with or without intubation, in the electronic medical record. Results: From August 15, 2024 through August 15, 2025, a total of 204 Rh(D)‐negative patients met the above criteria and were approved to receive routine Rh(D)‐positive RBC transfusions. Within that group, 23 patients received Rh(D)‐positive RBCs. The remaining patients either did not require transfusion or were issued Rh(D)‐negative RBC units. Since implementing this practice, a total of 68 Rh(D)‐negative units were conserved during this time frame. Notably, 28 of the 68 units (41%) were type O, Rh(D)‐negative. Discussion: Rh(D)‐positive RBCs can be routinely given to non‐alloimmunized Rh(D)‐negative patients who are not at risk for developing hemolytic disease of the fetus and newborn (HDFN). By creating clear guidelines for the routine administration of Rh(D)‐positive RBCs to patients who are not at risk for HDFN, the inventory of Rh(D)‐negative RBC units can be directed to those patients who would most benefit from this limited resource.
- 22 September 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (12) , E454-E456
Liquid biopsies in blood donors: Issues in implementing cell‐free DNA cancer screening tests in the blood donor population
Issues in implementing cell-free DNA cancer screening tests in blood donors.
- 22 September 2022
- Published by Wiley in American Journal of Hematology
- Vol. 97 (12) , E454-E456
Liquid biopsies in blood donors: Issues in implementing cell‐free DNA cancer screening tests in the blood donor population
Issues in implementing cell-free DNA cancer screening tests in blood donors.
- 17 March 2021
- Published by Wiley in Transfusion
- Vol. 61 (5) , 1361-1362
Iatrogenic arteriovenous fistula in patient with sickle cell disease undergoing red blood cell exchange
- 17 March 2021
- Published by Wiley in Transfusion
- Vol. 61 (5) , 1361-1362
Iatrogenic arteriovenous fistula in patient with sickle cell disease undergoing red blood cell exchange
- Open Access
- 1 January 2019
- Published by Walter de Gruyter GmbH in Immunohematology
- Vol. 35 (3) , 91-94
Dilution is not the solution: acute hemolytic transfusion reaction after ABO-incompatible pooled platelet transfusion
The short shelf life of platelets makes providing ABO-compatible platelets a challenge, and many institutions issue ABO-incompatible platelets when compatible units are not available. It is presumed that ABO antibodies that exist in donor plasma are diluted when platelets from multiple donors are combined to make a pooled product for transfusion. We present a case of a hemolytic transfusion reaction in a 73-year-old man with myelodysplastic syndrome who received an ABO-incompatible pooled platelet unit. This case report demonstrates that the dilution theory is not always true for pooled platelet units, and any patient receiving ABO-incompatible platelet transfusions must be closely monitored for potential hemolytic transfusion reactions.
- 1 January 2019
- Published by Walter de Gruyter GmbH in Immunohematology
- Vol. 35 (3) , 91-94
Open AccessDilution is not the solution: acute hemolytic transfusion reaction after ABO-incompatible pooled platelet transfusion
The short shelf life of platelets makes providing ABO-compatible platelets a challenge, and many institutions issue ABO-incompatible platelets when compatible units are not available. It is presumed that ABO antibodies that exist in donor plasma are diluted when platelets from multiple donors are combined to make a pooled product for transfusion. We present a case of a hemolytic transfusion reaction in a 73-year-old man with myelodysplastic syndrome who received an ABO-incompatible pooled platelet unit. This case report demonstrates that the dilution theory is not always true for pooled platelet units, and any patient receiving ABO-incompatible platelet transfusions must be closely monitored for potential hemolytic transfusion reactions.